Skip to main content
. 2021 Mar 23;15:631501. doi: 10.3389/fnins.2021.631501

FIGURE 6.

FIGURE 6

AS-IV (100 μM) protected 6-OHDA-treated SH-SY5Y cells via activating the JAK2/STAT3 pathway. The JAK2/STAT3 pathway inhibitor SC99 (15 mM) was added to the cells treated with AS-IV (100 μM), with PBS as the control. (A) Levels of p-JAK2/JAK2 and p-STAT3/STAT3 were detected using Western blot analysis. (B) Viability of 6-OHDA-treated SH-SY5Y cells was detected using MTT assay. (C) Apoptosis rate of 6-OHDA-treated SH-SY5Y cells was detected flow cytometry. (C) Levels of IL-1β, IL-6, and TNF-α in 6-OHDA-treated SH-SY5Y cells were detected using the ELISA kits. (D) Changes of MDA, ROS and SOD levels in 6-OHDA-treated SH-SY5Y cells were detected using corresponding kits. Each experiment was repeated for three times independently. Data are presented as mean ± standard deviation. Data in panels (A–F) were analyzed using t test, **p < 0.01 vs. AS-IV ± PBS group.